<DOC>
	<DOC>NCT02764606</DOC>
	<brief_summary>CANPOS is a non-interventional study aiming at evaluate at the time of initial surgery the value of new serum markers to predict the occurrence of metastases in patients with early-stage non-small cell lung cancer. This would represent a rational to develop personalized follow-up and prevention strategies</brief_summary>
	<brief_title>CANPOS: Predictive Biomarkers of Tumor Progression in Non-small Cell Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
	<criteria>patients with a diagnosis or suspected for a diagnosis of lung cancer, nonsmall cell lung cancer age over 18 years patient na√Øve of any oncology treatment (excluding surgery alone) within the past 5 years patient who signed the informed consent by the study protocol Exclusion criteria were: any ongoing treatment for cancer any history of cancer within 5 years before the diagnosis of lung cancer any psychological, sociological or geographical conditions that would not allow the study followup</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Lung Cancer</keyword>
	<keyword>Biomarkers</keyword>
	<keyword>Bone</keyword>
	<keyword>Metastases</keyword>
</DOC>